These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29940249)

  • 1. Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy.
    Kang M; Park JY; Jeong CW; Hwang EC; Song C; Hong SH; Kwak C; Chung J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
    J Urol; 2018 Nov; 200(5):989-995. PubMed ID: 29940249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
    Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
    Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
    Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
    Urol Oncol; 2017 Sep; 35(9):542.e1-542.e9. PubMed ID: 28619633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Yoshida K; Omae K; Iizuka J; Kobayashi H; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):559-567. PubMed ID: 29327159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.
    Santini D; Santoni M; Conti A; Procopio G; Verzoni E; Galli L; di Lorenzo G; De Giorgi U; De Lisi D; Nicodemo M; Maruzzo M; Massari F; Buti S; Altobelli E; Biasco E; Ricotta R; Porta C; Vincenzi B; Papalia R; Marchetti P; Burattini L; Berardi R; Muto G; Montironi R; Cascinu S; Tonini G
    Oncotarget; 2016 May; 7(22):33381-90. PubMed ID: 27027342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
    Harada K; Nozawa M; Uemura M; Tatsugami K; Osawa T; Yamana K; Kimura G; Fujisawa M; Nonomura N; Eto M; Shinohara N; Tomita Y; Kondo Y; Ochi K; Anazawa Y; Uemura H
    Int J Urol; 2019 Feb; 26(2):202-210. PubMed ID: 30345560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.
    Ito K; Mikami S; Tatsugami K; Masumori N; Shinohara N; Kondo T; Nakanishi S; Nagashima Y; Eto M; Kamba T; Kuroda N; Tomita Y; Matsuyama H; Onishi T; Tsushima T; Nakazawa H; Oya M; Ozono S; Naito S; Asano T
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1201-e1214. PubMed ID: 30224330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma.
    Zhu Y; Hong YP; Zhang HL; Shi GH; Xiao WJ; Wang ZH; Yao XD; Zhang SL; Dai B; Ye DW
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1901-7. PubMed ID: 22744643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma.
    Li JR; Ou YC; Yang CK; Wang SS; Chen CS; Ho HC; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Hung SC; Hsu CY; Chiu KY
    Anticancer Res; 2018 Sep; 38(9):5339-5345. PubMed ID: 30194186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
    Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
    Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
    Ueda K; Suekane S; Hirano T; Ogasawara N; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Anticancer Res; 2018 Sep; 38(9):5387-5392. PubMed ID: 30194193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Tyrosine Kinase Inhibitor
    Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors.
    Shin SJ; Kim T; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI; Kang M
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1137-e1146. PubMed ID: 31473122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.